Fertility protection: complications of surgery and results of removal and transplantation of ovarian tissue

Beckmann, Matthias W.; Dittrich, Ralf; Lotz, Laura; Ven, Karin van der; Ven, H. H. Van Der; Liebenthron, Jana; Korell, M.; Frambach, Torsten; Sütterlin, Marc; Schwab, Roxana; Seitz, S; Müller, Andreas; Wolff, Michael von; Häberlin, Felix; Henes, Melanie; Winkler-Crepaz, Katharina; Krüssel, Jan-Steffen; Germeyer, Ariane; Tóth, Bettina

doi:10.1016/j.rbmo.2017.10.109

Cited by 57 publications

(50 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In such cases, the live birth rate per transplant was roughly estimated to be $25%. Ovarian tissue vitrification and heterotopic autotransplantation have resulted in few reported live births [153][154][155][156][157].…”

Section: Experimental Optionsmentioning

confidence: 99%

Preserving fertility in female patients with hematological malignancies: a multidisciplinary oncofertility approach

2019

View full text Add to dashboard Cite

Oncofertility is a new interdisciplinary field at the intersection of oncology and reproductive medicine that expands fertility options for young cancer patients. The most common forms of hematological malignancies that occur in girls and young women and therefore necessitate oncofertility care are acute lymphocytic leukemia, acute myeloid leukemia, non-Hodgkin's lymphoma, and Hodgkin's lymphoma. Aggressive gonadotoxic anticancer regimens including alkylating chemotherapy and total body irradiation are used often in treating girls and young women with hematological malignancies. The risks of gonadotoxicity and subsequent iatrogenic premature ovarian insufficiency and fertility loss depend mainly on the type and stage of the disease, dose of anticancer therapy as well as the age of the patient at the beginning of treatment. To avoid or at least mitigate the devastating complications of anticancer therapy-induced gonadotoxicity, effective and comprehensive strategies that integrate different options for preserving and restoring fertility ranging from established to experimental strategies should be offered before, during, and after chemotherapy or radiotherapy. A multidisciplinary approach that involves strong coordination and collaboration between hemato-oncologists, gynecologists, reproductive biologists, research scientists, and patient navigators is essential to guarantee high standard of care.

show abstract

Section: Experimental Optionsmentioning

confidence: 99%

Preserving fertility in female patients with hematological malignancies: a multidisciplinary oncofertility approach

2019

View full text Add to dashboard Cite

show abstract

“…Though OTC is currently considered an experimental technique, over 130 births have been reported after OTC and autologous transplantation worldwide [8][9][10][11][12][13][14][15]. The success of OTC along with low rates of complication has led many experts to contend that the experimental label should now be removed [16,17].…”

Section: Introductionmentioning

confidence: 99%

Ovarian tissue cryopreservation (OTC) in prepubertal girls and young women: an analysis of parents’ and patients’ decision-making

Sullivan-Pyke

Carlson

Prewitt

et al. 2018

J Assist Reprod Genet

View full text Add to dashboard Cite

show abstract

“…One of the most important aspects of fertility preservation in patients undergoing cancer treatment is that the cancer treatment has priority, and fertility preservation therapy should be conducted without adversely affecting cancer treatment. According to a report, complications occurred in 0.2% of patients who underwent ovarian cryopreservation (3/1302) 16 . In one of these three patients, aspiration pneumonia occurred as a postoperative complication.…”

Section: Discussionmentioning

confidence: 99%

Ovarian cryopreservation for children aged 3 years or younger: A report of three cases

Kasei

Morimune

Kimura

et al. 2020

J of Obstet and Gynaecol

View full text Add to dashboard Cite

Ovarian tissue cryopreservation has recently been performed as an option for fertility preservation in prepubertal girls with cancer. In this study, ovarian tissue was cryopreserved from 3 girls of 3 years of age or younger during a 3-year period at our institution. Case 1 was a 1-year-old girl, who was diagnosed with a yolk sac tumor in the sacral region. Case 2 was a 2-year-old girl, who was diagnosed with retroperitoneal neuroblastoma. Case 3 was a 3-year-old girl, who was diagnosed with cerebellar medulloblastoma. All patients had planned to undergo chemotherapy that would affect the ovarian reserve. Because these patients were toddlers, consideration of ethics, the surgical procedure and postoperative management, and optimal method for freezing ovarian tissue was necessary, although gynecologists rarely experience these challenges in daily clinical practice. We herein present the clinical course of these three cases and discuss the peculiarities and countermeasures of ovarian cryopreservation in children.

show abstract

Fertility protection: complications of surgery and results of removal and transplantation of ovarian tissue

Cited by 57 publications

References 37 publications

Preserving fertility in female patients with hematological malignancies: a multidisciplinary oncofertility approach

Preserving fertility in female patients with hematological malignancies: a multidisciplinary oncofertility approach

Ovarian tissue cryopreservation (OTC) in prepubertal girls and young women: an analysis of parents’ and patients’ decision-making

Ovarian cryopreservation for children aged 3 years or younger: A report of three cases

Contact Info

Product

Resources

About